常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.85/-0.94
|
|
企業價值
211.20M
|
| 資產負債 |
|
每股賬面淨值
0.49
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
8.00K
|
|
每股收益
0.30
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/11/16 15:48 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer. |

5.32 
